• Mutation; HGNC; HGNC:644; AR; Simple; p.Thr878Ala (c.2632A>G); ClinVar=VCV000009831; Zygosity=Hemizygous (from parent cell line).
  
• Mutation; HGNC; HGNC:7010; MEN1; Simple; p.Tyr318Ter (c.954T>G) (p.Tyr313Ter, c.939T>A); ClinVar=VCV000439894; Zygosity=Heterozygous (from parent cell line).
  
• Mutation; HGNC; HGNC:8979; PIK3R1; Simple; p.Arg639Ter (c.1915C>T); Zygosity=Heterozygous (from parent cell line).
  
• Mutation; HGNC; HGNC:9588; PTEN; Simple; p.Lys6Argfs*4 (c.17_18delAA); ClinVar=VCV000231649; Zygosity=Unspecified (from parent cell line).
  

PubMed=25428917; DOI=10.18632/oncotarget.2703; PMCID=PMC4381591
Bishop J.L., Sio A., Angeles A., Roberts M.E., Azad A.A., Chi K.N., Zoubeidi A.
PD-L1 is highly expressed in enzalutamide resistant prostate cancer.
Oncotarget 6:234-242(2015)

PubMed=25634993; DOI=10.1158/1078-0432.CCR-14-1108
Yamamoto Y., Loriot Y., Beraldi E., Zhang F., Wyatt A.W., Al Nakouzi N., Mo F., Zhou T.-Y., Kim Y., Monia B.P., MacLeod A.R., Fazli L., Wang Y.-Z., Collins C.C., Zoubeidi A., Gleave M.E.
Generation 2.5 antisense oligonucleotides targeting the androgen receptor and its splice variants suppress enzalutamide-resistant prostate cancer cell growth.
Clin. Cancer Res. 21:1675-1687(2015)